Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.

ABCB1 (P-glycoprotein/P-gp) is an ATP-binding cassette transporter well known for its association with multidrug resistance in cancer cells. Powered by the hydrolysis of ATP, it effluxes structurally diverse compounds. In this chapter, we discuss current views on the molecular basis of the substrate polyspecificity of P-gp. One of the features that accounts for this property is the structural flexibility observed in P-gp. Several X-ray crystal structures of mouse P-gp have been published recently in the absence of nucleotide, with and without bound inhibitors. All the structures are in an inward-facing conformation exhibiting different degrees of domain separation, thus revealing a highly flexible protein. Biochemical and biophysical studies also demonstrate this flexibility in mouse as well as human P-gp. Site-directed mutagenesis has revealed the existence of multiple transport-active binding sites in P-gp for a single substrate. Thus, drugs can bind at either primary or secondary sites. Biochemical, molecular modeling, and structure-activity relationship studies suggest a large, common drug-binding pocket with overlapping sites for different substrates. We propose that in addition to the structural flexibility, the molecular or chemical flexibility also contributes to the binding of substrates to multiple sites forming the basis of polyspecificity.

[1]  D. Clarke,et al.  Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. , 2006, The Biochemical journal.

[2]  A. Seelig A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[3]  D. Clarke,et al.  Permanent Activation of the Human P-glycoprotein by Covalent Modification of a Residue in the Drug-binding Site* , 2003, Journal of Biological Chemistry.

[4]  D. Clarke,et al.  Human P-glycoprotein is active when the two halves are clamped together in the closed conformation. , 2010, Biochemical and biophysical research communications.

[5]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[6]  G. Chang,et al.  Design and Synthesis of Selenazole‐Containing Peptides for Cocrystallization with P‐Glycoprotein , 2011, Chembiochem : a European journal of chemical biology.

[7]  I. Pajeva,et al.  Interactions of the Multidrug Resistance Modulators Tariquidar and Elacridar and their Analogues with P‐glycoprotein , 2013, ChemMedChem.

[8]  Z. Sauna,et al.  Correlation between Steady-state ATP Hydrolysis and Vanadate-induced ADP Trapping in Human P-glycoprotein , 2001, The Journal of Biological Chemistry.

[9]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[10]  D. Tieleman,et al.  P‐glycoprotein models of the apo and ATP‐bound states based on homology with Sav1866 and MalK , 2007, FEBS letters.

[11]  D. Clarke,et al.  The Transmembrane Domains of the Human Multidrug Resistance P-glycoprotein Are Sufficient to Mediate Drug Binding and Trafficking to the Cell Surface* , 1999, The Journal of Biological Chemistry.

[12]  Eszter Hazai,et al.  Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein , 2011, PloS one.

[13]  D. Rees,et al.  Structural Basis for Heavy Metal Detoxification by an Atm1-Type ABC Exporter , 2014, Science.

[14]  D. Clarke,et al.  Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.

[15]  D. Clarke,et al.  Identification of Residues in the Drug-binding Site of Human P-glycoprotein Using a Thiol-reactive Substrate* , 1997, The Journal of Biological Chemistry.

[16]  P. Biggin,et al.  Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump , 2013, Proceedings of the National Academy of Sciences.

[17]  D. Clarke,et al.  Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. , 2006, The Biochemical journal.

[18]  M. R. Lugo,et al.  Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. , 2005, Biochemistry.

[19]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[20]  D. Baillie,et al.  The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes , 2004, Genome Biology.

[21]  D. Clarke,et al.  The Packing of the Transmembrane Segments of Human Multidrug Resistance P-glycoprotein Is Revealed by Disulfide Cross-linking Analysis* , 2000, The Journal of Biological Chemistry.

[22]  M. R. Lugo,et al.  Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. , 2005, Biochemistry.

[23]  In-Wha Kim,et al.  The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Erik Evensen,et al.  A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. , 2002, Journal of medicinal chemistry.

[25]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[26]  I. Pajeva,et al.  Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). , 2002, Journal of medicinal chemistry.

[27]  D. Clarke,et al.  Identification of Residues within the Drug-binding Domain of the Human Multidrug Resistance P-glycoprotein by Cysteine-scanning Mutagenesis and Reaction with Dibromobimane* , 2000, The Journal of Biological Chemistry.

[28]  S. Ambudkar,et al.  Multidrug Resistance in Cancer: A Tale of ABC Drug Transporters , 2013 .

[29]  R. Callaghan,et al.  The translocation mechanism of P‐glycoprotein , 2006, FEBS letters.

[30]  Michael Börsch,et al.  Dynamic Ligand-induced Conformational Rearrangements in P-glycoprotein as Probed by Fluorescence Resonance Energy Transfer Spectroscopy* , 2011, The Journal of Biological Chemistry.

[31]  D. Clarke,et al.  Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.

[32]  R. Callaghan,et al.  The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis , 2014, The FEBS journal.

[33]  R. Plasterk,et al.  A P‐glycoprotein protects Caenorhabditis elegans against natural toxins. , 1995 .

[34]  V. Ling,et al.  Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. , 2001, European journal of biochemistry.

[35]  Xuefeng Bruce Ling,et al.  Significance Analysis and Multiple Pharmacophore Models for Differentiating P-Glycoprotein Substrates , 2007, J. Chem. Inf. Model..

[36]  Stephan Kopp,et al.  Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 , 2007, ChemMedChem.

[37]  Stephen G Aller,et al.  Refined structures of mouse P-glycoprotein , 2013, Protein science : a publication of the Protein Society.

[38]  Gerhard F. Ecker,et al.  In silico prediction of substrate properties for ABC-multidrug transporters , 2008 .

[39]  Conserved Walker A cysteines 431 and 1074 in human P-glycoprotein are accessible to thiol-specific agents in the apo and ADP-vanadate trapped conformations. , 2013, Biochemistry.

[40]  L. Greenberger,et al.  Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. , 1993, The Journal of biological chemistry.

[41]  J. A. Nelson,et al.  Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. , 1994, The Journal of pharmacology and experimental therapeutics.

[42]  Ricardo J. Ferreira,et al.  Toward a Better Pharmacophore Description of P-Glycoprotein Modulators, Based on Macrocyclic Diterpenes from Euphorbia Species , 2011, J. Chem. Inf. Model..

[43]  R. Dawson,et al.  Structure and mechanism of ABC transporter proteins. , 2007, Current opinion in structural biology.

[44]  Christoph Globisch,et al.  Combined Pharmacophore Modeling, Docking, and 3D QSAR Studies of ABCB1 and ABCC1 Transporter Inhibitors , 2009, ChemMedChem.

[45]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[46]  D. Clarke,et al.  Defining the Drug-binding Site in the Human Multidrug Resistance P-glycoprotein Using a Methanethiosulfonate Analog of Verapamil, MTS-verapamil* , 2001, The Journal of Biological Chemistry.

[47]  Stephan Kopp,et al.  P-Glycoprotein Substrate Binding Domains Are Located at the Transmembrane Domain/Transmembrane Domain Interfaces: A Combined Photoaffinity Labeling-Protein Homology Modeling Approach , 2005, Molecular Pharmacology.

[48]  O. Jardetzky,et al.  Simple Allosteric Model for Membrane Pumps , 1966, Nature.

[49]  Geoffrey Chang,et al.  Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. , 2010, Trends in biochemical sciences.

[50]  Jue Chen,et al.  Crystal structure of the multidrug transporter P-glycoprotein from C. elegans , 2012, Nature.

[51]  V. Ling,et al.  Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. , 1997, European journal of biochemistry.

[52]  Matthew P. Jacobson,et al.  Predicting Binding to P-Glycoprotein by Flexible Receptor Docking , 2011, PLoS Comput. Biol..

[53]  A. E. Senior,et al.  The catalytic cycle of P‐glycoprotein , 1995, FEBS letters.

[54]  A. di Pietro,et al.  Understanding polyspecificity within the substrate‐binding cavity of the human multidrug resistance P‐glycoprotein , 2014, The FEBS journal.

[55]  Michael M Gottesman,et al.  Structure of a multidrug transporter , 2009, Nature Biotechnology.

[56]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[57]  Zahida Parveen,et al.  Molecular Dissection of Dual Pseudosymmetric Solute Translocation Pathways in Human P-Glycoprotein , 2011, Molecular Pharmacology.

[58]  Z. Sauna,et al.  Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Barr,et al.  Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states , 2013, Proceedings of the National Academy of Sciences.

[60]  F. Sharom,et al.  ABC efflux pump-based resistance to chemotherapy drugs. , 2009, Chemical reviews.

[61]  H. Sitte,et al.  Pore-Exposed Tyrosine Residues of P-Glycoprotein Are Important Hydrogen-Bonding Partners for Drugs , 2014, Molecular Pharmacology.

[62]  P. Biggin,et al.  Towards understanding promiscuity in multidrug efflux pumps. , 2014, Trends in biochemical sciences.

[63]  S. Ambudkar,et al.  Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein* , 1997, The Journal of Biological Chemistry.

[64]  S. Ambudkar,et al.  Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach , 2014, Molecular pharmaceutics.

[65]  I. Pajeva,et al.  Protein Contacts and Ligand Binding in the Inward‐Facing Model of Human P‐Glycoprotein , 2013, ChemMedChem.

[66]  M. Ramachandra,et al.  Functional Characterization of Glycosylation-Deficient Human P-Glycoprotein Using A Vaccinia Virus Expression System , 2000, The Journal of Membrane Biology.

[67]  D. Clarke,et al.  Substrate-induced Conformational Changes in the Transmembrane Segments of Human P-glycoprotein , 2003, The Journal of Biological Chemistry.

[68]  R. Schimke,et al.  Peptide transport by the multidrug resistance pump. , 1992, The Journal of biological chemistry.

[69]  S. Durell,et al.  Multiple Transport-Active Binding Sites Are Available for a Single Substrate on Human P-Glycoprotein (ABCB1) , 2013, PloS one.

[70]  Hassane S. Mchaourab,et al.  On the Origin of Large Flexibility of P-glycoprotein in the Inward-facing State* , 2013, The Journal of Biological Chemistry.

[71]  S. Wilkens,et al.  P-glycoprotein Retains Drug-stimulated ATPase Activity upon Covalent Linkage of the Two Nucleotide Binding Domains at Their C-terminal Ends* , 2011, The Journal of Biological Chemistry.

[72]  E. Pardon,et al.  Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain , 2013, Proceedings of the National Academy of Sciences.

[73]  J. Drewe,et al.  Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. , 2000, Molecular pharmacology.

[74]  Adam B. Shapiro,et al.  Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. , 1998, European journal of biochemistry.

[75]  I. Pastan,et al.  Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Geoffrey Chang,et al.  Flexibility in the ABC transporter MsbA: Alternating access with a twist , 2007, Proceedings of the National Academy of Sciences.

[77]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[78]  F. Sharom Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function , 2014, Front. Oncol..